Rein Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Rein Therapeutics, Inc. (RNTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.02 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-14
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $3.82.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $0.39, a 67.77% decline year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $1.21, a 175.00% increase year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $0.44, a 55.56% decline year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.26, a 48.78% decline from fiscal 2024.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $2.46, a 207.50% increase from fiscal 2023.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $0.80, a 89.07% decline from fiscal 2022.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $7.32, a 62.27% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.02 10-Q · filed 2026-08-14 | |||||
| 2025-12-31 | $1.26 10-K · filed 2026-03-26 | |||||
| 2025-09-30 | $1.26 10-Q · filed 2025-11-14 | |||||
| 2025-06-30 | $2.47 10-Q · filed 2025-08-14 | |||||
| 2024-12-31 | $2.46 10-K · filed 2026-03-26 | |||||
| 2024-09-30 | $2.46 10-Q · filed 2025-11-14 | |||||
| 2024-06-30 | $2.47 10-Q · filed 2024-08-14 | |||||
| 2024-03-31 | $3.82 10-Q · filed 2025-05-15 | |||||
| 2023-12-31 | $0.80 10-K · filed 2025-04-07 | |||||
| 2022-12-31 | $7.32 10-K · filed 2024-04-15 | |||||
| 2022-09-30 | $7.00 10-Q · filed 2023-10-13 | $0.35 10-Q · filed 2022-11-01 | ||||
| 2022-06-30 | $0.35 10-Q · filed 2023-08-11 | |||||
| 2022-03-31 | $0.39 10-Q · filed 2023-05-08 | |||||
| 2021-12-31 | $19.40 10-K · filed 2023-03-20 | $0.97 10-K · filed 2022-03-28 | ||||
| 2021-09-30 | $0.97 10-Q · filed 2022-11-01 | |||||
| 2021-06-30 | $0.97 10-Q · filed 2022-08-15 | |||||
| 2021-03-31 | $1.21 10-Q · filed 2022-05-05 | |||||
| 2020-12-31 | $0.51 10-K · filed 2022-03-28 | |||||
| 2020-09-30 | $0.48 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | $0.48 10-Q · filed 2021-08-11 | |||||
| 2020-03-31 | $0.44 10-Q · filed 2021-05-11 | |||||
| 2019-12-31 | $1.11 10-K · filed 2021-03-24 | |||||
| 2019-09-30 | $1.11 10-Q · filed 2020-11-12 | |||||
| 2019-06-30 | $1.11 10-Q · filed 2020-08-05 | |||||
| 2019-03-31 | $0.99 10-Q · filed 2020-05-11 | |||||
| 2018-12-31 | $2.57 10-K · filed 2020-03-30 | |||||
| 2018-09-30 | $3.65 10-Q · filed 2019-11-07 | |||||
| 2018-06-30 | $4.79 10-Q · filed 2019-08-06 | |||||
| 2018-03-31 | $6.17 10-Q · filed 2019-05-08 | |||||
| 2017-12-31 | $7.49 10-K · filed 2019-03-29 | |||||
| 2017-09-30 | $7.51 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | $5.98 10-Q · filed 2018-08-07 | |||||
| 2017-03-31 | $4.43 10-Q · filed 2018-05-09 | |||||
| 2016-12-31 | $3.24 10-K · filed 2018-04-02 | |||||
| 2016-09-30 | $3.24 10-Q · filed 2017-11-09 | |||||
| 2016-06-30 | $3.24 10-Q · filed 2017-08-10 | |||||
| 2015-12-31 | $3.69 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |